Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McKenna & Cuneo "stay of action" Nicorette petition denied by FDA.

This article was originally published in The Tan Sheet

Executive Summary

NICORETTE EXCLUSIVITY DECISION "STAY OF ACTION" NOT WARRANTED, FDA concludes in an Oct. 31 letter from Center for Drug Evaluation & Research Director Janet Woodcock, MD, to McKenna & Cuneo attorney Gary Yingling. The D.C. law firm, representing an unnamed client, requested in a Feb. 16 citizen petition that if relief sought in its November 1995 petition requesting denial of exclusivity for the OTC smoking cessation chewing gum were turned down, FDA Commissioner David Kessler should "stay issuance of market exclusivity to Nicorette until the completion of judicial review of the agency's decision." FDA says it "does not agree that a stay of action is warranted."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel